Lan Lan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lan Lan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Chen Wu
Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
18 shared publications - Dongxin Lin
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China and Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China; Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China
18 shared publications - Guoyu Cheng
Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) 1 Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital Beijing, China
18 shared publications - Jiang Chang
Department of Health Toxicology, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College Huazhong University of Science and Technology Wuhan China
18 shared publications - Li Zhang
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
18 shared publications - Liang Zhu
Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) 1 Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital Beijing, China
18 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S11. Gating strategies for flow cytometry analysis
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S11. Gating strategies for flow cytometry analysis
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S9. Characterization of predictive biomarkers in the retrospective and prospective cohorts
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S9. Characterization of predictive biomarkers in the retrospective and prospective cohorts
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S2. Detailed plasma sampling time points in the longitudinal analysis cohorts
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S2. Detailed plasma sampling time points in the longitudinal analysis cohorts
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S3. The clinicopathologic information of treatment-naïve ESCC patients
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S3. The clinicopathologic information of treatment-naïve ESCC patients
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S5. SOX2 is the key transcriptional regulator of GPNMB in ESCC
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S5. SOX2 is the key transcriptional regulator of GPNMB in ESCC
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S4. Differentially expressed plasma proteins between non-responders (NR) and responders (R) identified by proteomic analysis
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S4. Differentially expressed plasma proteins between non-responders (NR) and responders (R) identified by proteomic analysis
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S4. Tumor-derived soluble GPNMB is the critical mediator of CD8⁺ T cell exhaustion and immune evasion
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S4. Tumor-derived soluble GPNMB is the critical mediator of CD8⁺ T cell exhaustion and immune evasion
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S3. GPNMB induces CD8⁺ T cell exhaustion via SDC4-CD148 axis and suppresses anti-tumor immunity in vivo
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S3. GPNMB induces CD8⁺ T cell exhaustion via SDC4-CD148 axis and suppresses anti-tumor immunity in vivo
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S1. GPNMB is upregulated in ESCC and associated with immunotherapy resistance
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S1. GPNMB is upregulated in ESCC and associated with immunotherapy resistance
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S2. GPNMB suppresses CD8⁺ T cell function in vitro
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S2. GPNMB suppresses CD8⁺ T cell function in vitro